Understanding how mutations in a specific receptor affect blood cancer progression
Mechanisms of differentiation blockade in CSF3R-mutant AML
This study is looking at how changes in a specific gene, CSF3R, make Acute Myeloid Leukemia (AML) more aggressive by preventing blood cells from maturing properly, and it hopes to find new ways to help patients with this tough condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-11015004 on NIH RePORTER |
What this research studies
This research investigates how mutations in the Colony Stimulating Factor 3 Receptor (CSF3R) contribute to the aggressive nature of Acute Myeloid Leukemia (AML). The study focuses on the inability of mutant CSF3R to promote the differentiation of blood cells into mature neutrophils, which is crucial for normal immune function. By examining the genetic alterations that accompany CSF3R mutations, such as those in the CEBPA transcription factor, the research aims to uncover the mechanisms behind differentiation blockade in AML. This could lead to new insights into potential therapeutic targets for patients with this challenging condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with Acute Myeloid Leukemia, particularly those with mutations in the CSF3R gene.
Not a fit: Patients with other forms of leukemia that do not involve CSF3R mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for patients with CSF3R-mutant AML, potentially enhancing survival rates.
How similar studies have performed: Previous research has shown promising results in understanding genetic mutations in leukemia, suggesting that this approach could yield valuable insights.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Maxson, Julia E — Oregon Health & Science University
- Study coordinator: Maxson, Julia E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.